OrbiMed Advisors LLC's Form 4 filing
Sionna Therapeutics, Inc. (SION) · filed Feb 10, 2025
- Accession no.
- 0000947871-25-000120
- Filed
- Feb 10, 2025, 4:28 PM ET
- Trade date
- Feb 10, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $9.90M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Capital GP VIII LLCCIK 0001845804 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionAcquired | +3,154,959 | –F1 | – | 3,154,959 | Indirect | Duplicate filing |
| Feb 10, 2025 | Common Stock | PPurchaseAcquired | +550,000 | $18.00 | +$9,900,000 | 3,704,959 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionDisposed | −1,752,755 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −1,402,204 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.